pioglitazone has been researched along with Injuries, Spinal Cord in 5 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Pioglitazone is an FDA-approved PPAR-γ agonist drug used to treat diabetes, and it has demonstrated neuroprotective effects in multiple models of central nervous system (CNS) injury." | 1.46 | Pioglitazone treatment following spinal cord injury maintains acute mitochondrial integrity and increases chronic tissue sparing and functional recovery. ( Bailey, WM; Cox, DH; Geldenhuys, WJ; Gensel, JC; Gollihue, JL; Patel, SP; Rabchevsky, AG; Sullivan, PG, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Suzuki, Y | 1 |
| Nakagawa, S | 1 |
| Endo, T | 1 |
| Sotome, A | 1 |
| Yuan, R | 1 |
| Asano, T | 1 |
| Otsuguro, S | 1 |
| Maenaka, K | 1 |
| Iwasaki, N | 1 |
| Kadoya, K | 1 |
| Patel, SP | 1 |
| Cox, DH | 1 |
| Gollihue, JL | 1 |
| Bailey, WM | 2 |
| Geldenhuys, WJ | 1 |
| Gensel, JC | 2 |
| Sullivan, PG | 2 |
| Rabchevsky, AG | 1 |
| Donahue, RR | 1 |
| Taylor, BK | 1 |
| Yonutas, HM | 1 |
| McTigue, DM | 1 |
| Tripathi, R | 1 |
| Wei, P | 1 |
| Lash, AT | 1 |
1 review available for pioglitazone and Injuries, Spinal Cord
| Article | Year |
|---|---|
Targeting PPAR isoforms following CNS injury.
Topics: Animals; Brain Injuries; Drug Design; Humans; Mitochondrial Proteins; Molecular Targeted Therapy; Ne | 2013 |
4 other studies available for pioglitazone and Injuries, Spinal Cord
| Article | Year |
|---|---|
High-Throughput Screening Assay Identifies Berberine and Mubritinib as Neuroprotection Drugs for Spinal Cord Injury via Blood-Spinal Cord Barrier Protection.
Topics: Animals; Berberine; Endothelial Cells; High-Throughput Screening Assays; Humans; Hydrogen Peroxide; | 2022 |
Pioglitazone treatment following spinal cord injury maintains acute mitochondrial integrity and increases chronic tissue sparing and functional recovery.
Topics: Analysis of Variance; Animals; Calcium-Binding Proteins; Disease Models, Animal; Glial Fibrillary Ac | 2017 |
Sexual Dimorphism of Pain Control: Analgesic Effects of Pioglitazone and Azithromycin in Chronic Spinal Cord Injury.
Topics: Analgesics; Animals; Azithromycin; Chronic Pain; Female; Male; Mice; Mice, Inbred C57BL; Pioglitazon | 2019 |
The PPAR gamma agonist Pioglitazone improves anatomical and locomotor recovery after rodent spinal cord injury.
Topics: Animals; Apoptosis; Blood-Brain Barrier; Caspase 3; CD11b Antigen; Cell Count; Female; Hypoglycemic | 2007 |